Every 8-K that Regeneron Pharmaceuticals Inc (REGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow REGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REGN filings page.
Regeneron Pharmaceuticals reported second quarter 2026 revenue of $4.3 billion, up 17% versus second quarter 2025. GAAP net income was $1,297 million, down 7%, and GAAP diluted EPS was $12.23, including a $1.02 negative impact from IPR&D. Non-GAAP diluted EPS was $14.29, up 11%, including a $0.99 negative impact from IPR&D.
Product and collaboration trends were mixed. Dupixent global net sales recorded by Sanofi rose 38% to $6.0 billion, EYLEA HD U.S. net sales rose 52% to $596 million, and Libtayo global net sales rose 30% to $489 million. Total U.S. EYLEA HD and EYLEA net product sales fell 12% to $1,008 million, reflecting lower EYLEA demand and continued transition to EYLEA HD. The Sanofi Development Balance was fully repaid as of the end of the quarter and will no longer reduce Sanofi collaboration revenue beginning in the third quarter.
Regeneron also updated 2026 guidance, including GAAP R&D of $6.500–$6.635 billion, GAAP gross margin of 78%–79%, and capital expenditures of $1.030–$1.100 billion. Cemdisiran applications were accepted by the FDA and EMA for gMG, with FDA priority review and a November 2026 target action date.
Regeneron Pharmaceuticals, Inc. expects to record an acquired in-process research and development charge of approximately $127 million on a pre-tax basis in its second quarter 2026 results. This charge comes from up-front and opt-in payments tied to collaboration and licensing agreements.
The acquired IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share for the quarter by about $1.00. Regeneron notes these results are preliminary and subject to completion of financial closing procedures, and emphasizes that it does not forecast such charges because their timing and size are uncertain.
Regeneron Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Shareholders held on June 12, 2026. Shareholders elected five Class II directors to serve until the 2027 annual meeting, with each nominee receiving substantially more votes "For" than "Against."
Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 102,503,788 votes For and 6,443,958 Against. In addition, the advisory resolution approving executive compensation received 96,469,374 votes For and 6,898,268 Against, with 5,543,411 broker non-votes.
Regeneron Pharmaceuticals reported strong first quarter 2026 results, with total revenues rising 19% to $3.6 billion from $3.0 billion a year earlier, driven by Dupixent and oncology growth. GAAP net income declined 10% to $727 million as higher R&D, IPR&D and manufacturing costs weighed on margins, while non-GAAP net income increased 12% to $1.04 billion and diluted non‑GAAP EPS grew 15% to $9.47.
Dupixent global net sales recorded by Sanofi rose 33% to $4.9 billion, and Libtayo global net sales climbed 54% to $438 million. EYLEA HD U.S. net sales jumped 52% to $468 million, but combined U.S. EYLEA HD and EYLEA net sales fell 10% to $941 million amid competitive pressures and patient transition to EYLEA HD.
The quarter featured multiple regulatory wins, including FDA and EC approvals expanding Dupixent indications, extended EYLEA HD dosing intervals, and accelerated FDA approval of Otarmeni, which Regeneron will provide for free in the U.S. The company repurchased $803 million of stock, authorized a new $3.0 billion buyback, and declared a $0.94 per‑share dividend. Guidance for 2026 largely held, though GAAP gross margin on net product sales was trimmed to 77–78% due to a temporary manufacturing interruption in Ireland.
Regeneron Pharmaceuticals, Inc. expects to record an acquired in-process research and development charge of approximately $102 million on a pre-tax basis in its first quarter 2026 results. This stems mainly from premiums on equity securities and development milestone and up-front payments tied to collaboration and licensing agreements.
The company expects this acquired IPR&D charge to reduce both GAAP and non-GAAP net income per diluted share for the first quarter 2026 by approximately $0.81. These figures are preliminary, unaudited estimates and remain subject to completion of Regeneron’s financial statement closing procedures.
Regeneron Pharmaceuticals, Inc. filed a current report to furnish a press release announcing its financial and operating results for the fourth quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1 to the report.
The company states that the information provided under the results section, including Exhibit 99.1, is being furnished rather than filed under securities laws, which affects how it is treated for certain legal liabilities and incorporation by reference into other registration statements.
Regeneron Pharmaceuticals, Inc. used its appearance at the 44th Annual J.P. Morgan Healthcare Conference to share a corporate update that includes preliminary, unaudited financial information for the fourth quarter and full year 2025, furnished via an accompanying presentation.
For the fourth quarter 2025, Regeneron currently expects to record an acquired in-process research and development charge of approximately $19 million on a pre-tax basis, which is expected to reduce both GAAP and non-GAAP net income per diluted share by about $0.14. In addition, under its previously disclosed matching program supporting Good Days’ Retinal Vascular and Neovascular Disease Fund, Regeneron was notified of about $60 million in donations to the fund in the quarter, leading to a corresponding matching charge recorded in selling, general, and administrative expenses. All results remain preliminary and subject to completion of financial closing procedures.
Regeneron Pharmaceuticals (REGN) furnished a press release reporting financial and operating results for the quarter ended September 30, 2025.
The press release is attached as Exhibit 99.1 and incorporated by reference into Item 2.02. The company states this information is furnished, not filed, under the Exchange Act and is not incorporated into Securities Act filings unless specifically referenced.
Regeneron Pharmaceuticals expects to record an acquired in-process research and development charge of approximately $83 million on a pre-tax basis in its GAAP and non-GAAP financial results for the third quarter of 2025. This charge primarily reflects a previously disclosed $80 million up-front payment to Hansoh Pharmaceuticals Group Company Limited under a 2025 license agreement.
The acquired IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share for the third quarter of 2025 by approximately $0.68. Regeneron notes that it does not forecast acquired IPR&D charges because the timing and size of such transactions are uncertain, and it emphasizes that third-quarter 2025 results are preliminary and subject to completion of normal closing procedures.